Hibsago Opens a Narrow Path Beyond Lifelong Hepatitis B Suppression

The US Food and Drug Administration has approved Hibsago, or bepirovirsen, alongside existing antiviral therapy for certain adults with chronic hepatitis B. It is the first FDA-approved antisense oligonucleotide for the disease and the first US treatment designed to give some eligible patients a realistic route to sustained viral control after all hepatitis B medicines are stopped.

A different target, not a universal cure

Standard nucleos(t)ide analogue medicines can suppress hepatitis B virus for years, but they rarely remove the need for ongoing treatment. Bepirovirsen instead uses a short synthetic strand called an antisense oligonucleotide. It is designed to bind viral RNA, reducing production of viral genetic material and proteins, including hepatitis B surface antigen, or HBsAg.

The FDA indication is deliberately narrow. Patients must be adults without cirrhosis, must have taken antiviral therapy for at least six months, must already have suppressed HBV DNA, and must have HBsAg at or below 3,000 IU/mL on an authorized test. Hibsago is injected under the skin for up to 24 weeks. Existing antiviral treatment continues during that period and for at least 24 weeks afterward.

Across the two pivotal trials, 19% of Hibsago recipients still had undetectable HBV DNA and HBsAg 24 weeks after stopping all treatment, compared with none in the placebo groups.

What the trials actually showed

The B-Well 1 and B-Well 2 studies were randomized, double-blind, placebo-controlled phase 3 trials conducted across 29 countries. Together they enrolled more than 1,800 adults receiving background antiviral therapy. In the individual trials, functional cure at week 72 was recorded in 20% and 19% of bepirovirsen recipients, while no placebo recipient met the endpoint.

That is clinically important because it changes the goal from indefinite suppression to a finite treatment course for a subset of patients. It is not evidence that most people with chronic hepatitis B can stop treatment. About 81% of treated participants did not meet the functional-cure endpoint, and the trials excluded people with cirrhosis and those above the specified surface-antigen threshold.

Reality check: benefit comes with monitoring

The approval does not mean the virus has been eradicated from the body, and “functional cure” is a trial endpoint rather than sterilizing cure. It means HBV DNA and HBsAg remained undetectable for at least 24 weeks after all therapy stopped. Longer follow-up is still needed to establish durability and effects on later complications such as cirrhosis and liver cancer.

Hibsago also carries a boxed warning for serious liver reactions and low platelet counts, which can raise bleeding risk. Other warnings cover worsening kidney function, inflammatory reactions such as vasculitis, and risks from improper injection. Regular blood testing before and during therapy is therefore part of the treatment, not an optional precaution.

The approval marks a genuine change in what may be possible for a carefully selected group, but its value will depend on screening, access to quantitative HBsAg testing, safe monitoring, and evidence that viral control persists beyond the first six months off treatment.